1396259-53-2

Upstream product

• 90481-77-9 3-bromo-1-(4-methylbenzenesulfonyl)-1H-indole 
• 1396259-37-2 C₄₁H₃₉NO₆S 
• 120-72-9 indole 
• 31271-90-6 1-(p-toluenesulfonyl)-1H-indole 

Downstream Products

• 1396260-31-3 1-(4-propylbenzyl)-3-(β-D-xylopyranosyl)-1H-indole 
• 1396260-23-3 1-(4-cyclopropylbenzyl)-3-(β-D-xylopyranosyl)-1H-indole 
• 1396260-39-1 C₄₁H₃₉NO₄ 
• 1396260-51-7 C₄₅H₄₁NO₄ 
• 1396260-42-6 C₄₁H₃₈FNO₄ 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors

Sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors are the current focus on the indication for the management of hyperglycemia in diabetes. Here, a novel series of C-linked indolylxyloside-based inhibitors of SGLT2 has been discovered. Structure-activity relationship studies revealed that substituents at the 7-position of the indole moiety and a p-cyclopropylphenyl group in the distal position were necessary for optimum inhibitory activity. The pharmacokinetic study demonstrates that the most potent compound 1i is metabolically stable with a low clearance in rats. In further efficacy study, 1i is found to significantly lower blood glucose levels of streptozotocin (STZ)-induced diabetic rats.